Molecular Health launches cloud-based NGS decision support tool

DNA

Molecular Health debuted a pair of next-gen clinical decision support systems based on its cloud-based software. The tools will help clinicians better manage molecular information from the next-generation sequencing of their patients’ tumors.

The Molecular Health Guide tools are based on the company’s Dataome technology, which captures, integrates and analyzes the molecular outcomes data of patients who are mapped to biomedical literature, the company said in a statement.

The first tool, Workbench Manager, conducts a bioinformatics analysis of next-gen sequencing data from a patient’s tumor and creates a personalized report that includes treatment options that could potentially be effective as well as options that could be potentially ineffective. It also has a tool for matching patients to clinical trials. The Workbench Manager will help clinicians and laboratories reduce the time and cost of, as well as the errors that come with manually interpreting these data.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The second tool, dubbed the Clinical Annotation Service, automates the delivery of clinically reviewed annotations for actionable variants, that is, genetic variants that are associated with a known therapy. The data it returns include evidence-based treatment options, matching trials, drug descriptions and drug interactions, according to the statement. It is designed for use in high-throughput laboratories and any high-volume facility.

“Molecular Health Guide clinical decision support solutions help molecular pathologists and oncologists to more effectively manage molecular information from Next-Generation Sequencing of patient’s tumors, including the identification of potentially effective or potentially ineffective treatment and relevant clinical trials,” said Dr. Les Paul, Molecular Health’s chief medical officer and U.S. CEO, in the statement. “We have designed these offerings to strategically address the needs of oncologists and pathologists as well as large laboratory, hospital and research customers.”

Suggested Articles

Weeks after receiving FDA approval for its in-office eardrum tube device, Tusker Medical has been picked up by Smith & Nephew for an undisclosed sum.

As public fascination with at-home DNA tests begins to wane, 23andMe announced that it will lay off about 100 of its staff, according to CNBC.

The Rady Children’s Institute for Genomic Medicine tapped Deloitte to help develop a network of flying drones to deliver genetic testing specimens.